Following World Health Organization’s (WHO) guidelines
In high Tuberculosis (TB) burden countries, clinicians are often forced to start empirical antibiotic treatment without proper diagnosis, due to very limited or unavailability of user-friendly diagnostic tests that can provide confirmatory results. This often leads to suboptimal therapy with ineffective drugs, which not only fails to cure the patient but also allows further spread of drug-resistant TB in society and increases the risk of development of more resistant and refractory forms of TB. Therefore, WHO strongly recommends rapid molecular in first-line diagnostic monitoring for all suspected TB cases globally. EMPE provides such diagnostic test kits to significantly reduce the time required to initiate effective therapy for TB patients already at the initial contact between the patient and the health care facility.
Sample to result in 3 hours!
Customizable and suitable for
resource limited clinical laboratories
Cutting-edge multiplex test, yet simple to read
EMPE’s diagnostic platform is inexpensive, easy to use and provides reliable answers about the bacterium and its resistance profile. Our multiplex molecular test indicates presence of Mycobacterium tuberculosis and its genotypic resistance profile by developing a visual signal. Clinicians can get confirmatory results in a qualitative ‘YES’ or ‘NO’ format, within 3 h. As a result, doctors will be able to select the appropriate drugs enabling effective antibiotic treatment and limit transmission of MDR-TB.
Drug resistance in Tuberculosis
Drug resistance in Tuberculosis
Tuberculosis (TB) is a severe and potentially deadly infectious pulmonary disease caused by Mycobacterium tuberculosis. It is most prevalent in low- and middle-income countries but seen in every country around the globe and constitutes a difficult challenge to global public health. About 1.7 billion people are estimated to be infected worldwide, and 10 million develop active TB every year causing 1.5 million deaths. Asia and Africa are the two regions with the highest TB burden and India and China are the countries with the most cases.
Drug susceptible TB can be successfully cured by standard combination of well-known anti-TB drugs, but an increased incidence of resistance to these drugs leads to a less effective, longer (up to 24 months), and expensive treatment regimen with more side effects to the patient. Thus, the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) is an increasing global health concern that must be controlled. It is thus crucially important to rapidly detect drug resistance and initiate appropriate treatment in all patients to avoid transmission of these difficult forms of TB.
Among the 10 million TB cases reported globally in 2019, close to half a million developed resistance to rifampicin and 78% of these strains were identified as MDR-TB. The three high burden countries to report MDR-TB are India, China and Russia.
According to the end TB program, more than 40% of persons with TB are not detected and treated. Among the estimated number of drug-resistant cases, almost 80% do not receive effective drug therapy. Even though more than USD 9 billion is being spent on controlling TB, at least 3 million TB cases are not identified and offered correct treatment. Quick and reliable diagnosis is therefore of uttermost importance and urgently needed.
Countries that had at least 100 000 incident cases
of TB in 2019
The eight countries that rank first to eighth in terms of numbers of cases, and that accounted for two thirds of global cases in 2019, are labelled.
Source: Figure 2.3 from “Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO”
The global number of people reported to have been
treated for TB disease, 2015-2019
Source: Figure 2.6 from “Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO”
Our CEO, Dr. Pavan Asalapuram has presented a poster about the clinical performance validations of our first product, mfloDX® miniMDR-TB test kit at the 2019 World Conference on Access to Medical Products.Read More
Professor Sven Hoffner, our advisor presented a poster about the clinical performance validations of our first product, mfloDX® miniMDR-TB test kit at the 50th Union World Conference.Read More
EMPE diagnostics has offered an industrial project to a group of Applied Biotechnology MSc students from Uppsala University as a part of their Innovation Management and Entrepreneurship program.Read More